19.10.2017 Situated at the EPFL Innovation Park the Asceneuron team celebrated its 5 year anniversary on October 19, 2017 with friends and distinguished guests.
Asceneuron strives to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. Its lead product ASN120290, an O-GlcNAcase inhibitor which has been demonstrated to modulate tau pathology in preclinical studies, is nearing the completion of phase 1 clinical testing in healthy volunteers. ASN120290 is primarily being developed for the orphan tauopathy progressive supranuclear palsy with the potential for expansion into Alzheimer’s disease at a later stage. As highlighted in a presentation by Dirk Beher, CEO and a co-founder of the Asceneuron, in the next 5 years the company aims to bring urgently needed medicines to patients and to build an established rare diseases drug company.
A privately held company financed with over 40 million CHF by a strong syndicate of investors consisting of Sofinnova Partners, Merck Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma.